Conditioning, Immunosuppression, and G-CSF Posttransplantation
| . | BM Group . | PBSC Group . | CD34 Group . |
|---|---|---|---|
| No. of patients | 45 | 45 | 18 |
| Conditioning | |||
| Cy/TBI | 40* | 37† | — |
| Bu/Cy | 3 | 6‡ | 18 |
| Cy/TLI | 1 | — | — |
| Holoxan/TBI | 1 | — | — |
| Bu/VP16 | 1 | ||
| Cy/MEA | 1 | ||
| Immunosuppression | |||
| Pretransplant | |||
| ATG | 8 | 8 | 17 |
| OKT3 | 9 | 11 | — |
| Posttransplant | |||
| CsA + Mtx | 29 | 33 | 6 |
| CsA + Mtx + Pred | 12 | 11 | 1 |
| CsA + Pred | 3 | 1 | — |
| CsA | 1 | 0 | 8 |
| None | — | — | 3 |
| G-CSF | |||
| Patients receiving G-CSF | 13 | 17 | 7 |
| Median days with G-CSF | P = .04 | ||
| (range) | 16 (6-21) | 10 (4-19) | 5 (2-14) |
| P < .01 | |||
| . | BM Group . | PBSC Group . | CD34 Group . |
|---|---|---|---|
| No. of patients | 45 | 45 | 18 |
| Conditioning | |||
| Cy/TBI | 40* | 37† | — |
| Bu/Cy | 3 | 6‡ | 18 |
| Cy/TLI | 1 | — | — |
| Holoxan/TBI | 1 | — | — |
| Bu/VP16 | 1 | ||
| Cy/MEA | 1 | ||
| Immunosuppression | |||
| Pretransplant | |||
| ATG | 8 | 8 | 17 |
| OKT3 | 9 | 11 | — |
| Posttransplant | |||
| CsA + Mtx | 29 | 33 | 6 |
| CsA + Mtx + Pred | 12 | 11 | 1 |
| CsA + Pred | 3 | 1 | — |
| CsA | 1 | 0 | 8 |
| None | — | — | 3 |
| G-CSF | |||
| Patients receiving G-CSF | 13 | 17 | 7 |
| Median days with G-CSF | P = .04 | ||
| (range) | 16 (6-21) | 10 (4-19) | 5 (2-14) |
| P < .01 | |||
Abbreviations: Cy, cyclophosphamide; TBI, total body irradiation; Bu, Busulfan; TLI, total lymph node irradiation; MEA, melphalane, Etoposide, and Arabinoside C; ATG, antithymocyte globulin; CsA, cyclosporine; Mtx, methotrexate; Pred, prednisolone.
One patient also received VP16.
Two patients received VP16 and one received iterabicin.
One patient received thiotepa.